Frontlight ResearchEarly access
Active, not recruitingPhase 1
GDNF Gene Therapy for Multiple System Atrophy
Key facts
- Who runs it
- Brain Neurotherapy Bio, Inc.
- Where
- Boca Raton, Boston, Columbus, Farmington Hills, Irvine, Nashville, and New York, United StatesSee the 7 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 9 people, planned
- Started
- 3 Oct 2023
- Expected to end
- Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- AAV2-GDNF gene therapy
- Sham (Placebo) Surgery
- Record updated
- 30 January 2026
Who can take part
- Age
- 35 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male and female 35-75 years of age (inclusive)
- Clinical diagnosis of MSA, parkinsonian type with symptoms onset sporadic, progressive and > 30 years of age
- Less than 5 years from MSA parkinsonian diagnosis with expected survival more than 3 years
- Stable anti-parkinsonian medication regimen
- Ability to walk a distance of 25 feet with or without an assistive device
Who cannot take part
- Prior brain surgery (i.e., deep brain stimulator implantation) or other brain imaging abnormalities
- Received investigational agent within 12 weeks
- Presence of idiopathic Parkinson's disease (PD) or any PD-related mutation or other neurological diseases
- Presence of dementia, psychosis, substance abuse or poorly controlled depression
- History of cancer or poorly controlled medical conditions that would increase surgical risk
- Inability to tolerate laying flat in an MRI and/or allergy to gadolinium; NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Where in United States
- Parkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, United States
- Massachusetts General HospitalBoston, United States
- The Ohio State University Medical CenterColumbus, United States
- QUEST Research InstituteFarmington Hills, United States
- University of California, IrvineIrvine, United States
- Vanderbilt University Medical CenterNashville, United States
- NYU Langone HealthNew York, United States
About the trial
What the trial wants to find out
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.
The 2 groups in the trial
- Active TreatmentTreatment being tested
Treatment: AAV2-GDNF gene therapy
- Placebo SurgerySham treatment, for comparison
Treatment: Sham (Placebo) Surgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy
- Record updated
- 30 January 2026